TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06562894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily (QD)
Study: NCT06659094
Drug: conventional medical treatment (TAU)
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy, managed by a deputy chief psychiatrist unaware of patient groupings, utilizes China Food and Drug Administration (CFDA)-approved SSRIs for OCD. These include fluoxetine, paroxetine, sertraline, fluvoxamine, and others, with tricyclic drugs like clomipramine and SNRIs such as venlafaxine. The maximum dosage adheres to the instructions. Benzodiazepines may assist with sleep, but usage is capped at two weeks; no other psychotropics are co-administered. Common side effects comprise dry mouth, constipation, nausea, indigestion, dizziness, fatigue, and sweating. The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual.
Study: NCT05435781
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
Study: NCT05435781
Drug: Placebo for hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
Study: NCT05204862
Drug: TU2218
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered
Study: NCT06350890
Drug: HTD1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTD1801 1000 mg administered orally BID as four capsules
Study: NCT06350890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally BID as four capsules
Study: NCT05901441
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For those in SF group: they will be administered with 40 ug/ml sufentanil
Study: NCT06425549
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants receive placebo at pre-specified timepoints during the study to maintain the blinding.
Study: NCT06133751
Drug: black chokeberry (Aronia melanocarpa)
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black chokeberry capsules standardized for anthocyanin compounds
Study: NCT06133751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chokeberry fiber placebo capsules
Study: NCT06106412
Drug: A23187
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oocytes will be activated with A23187
Study: NCT05299554
Drug: Chronocort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone modified-release capsule 5 mg and 10 mg
Study: NCT05899517
Drug: oral lollipop with placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after placebo administration.
Study: NCT04717531
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, day 1
Study: NCT06387212
Drug: 35 kDa hyaluronan fragment HA35 injection
Normalized name: PALMITOYL FRAGMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: First, apply an appropriate amount of compound lidocaine cream to the treatment site ( national drug approval number H20063466 ; Beijing Ziguang Pharmaceutical Co., Ltd. ) waited for 60 minutes after applying hemp, and then injected the syringe containing sterile HA35 prepared in advance into the subcutaneous 1.0-1.5mm through the DermaShine PRO negative pressure microneedle importer ( Demasha, South Korea ).
Study: NCT05865496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous (SC) injection.
Study: NCT04971135
Drug: SAN711
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAN711 liquid formulation
Study: NCT05840211
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT04593511
Drug: LY03009 F1
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of LY03009 F1
Study: NCT04593511
Drug: LY03009 F2
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of LY03009 F2
Study: NCT04593511
Drug: LY03009 F3
Normalized name: MLK F3 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of LY03009 F3
Study: NCT04593511
Drug: LY03009 F4
Normalized name: MLK F4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of LY03009 F4
Study: NCT04954001
Drug: FCN-159
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-159 is administered orally in once daily schedule for 28 days a cycle.
Study: NCT06501391
Drug: PD-L1/PD-1 inhibitor and chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable brain metastases patients in this arm will receive PD-L1/PD-1 inhibitors and chemotherapy.
Study: NCT05752799
Drug: Opioid Free Anaesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 40 mg/kg magnesium sulfate in 100 ml N/S infusion~* 0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~* 0.3 mg/kg ketamine in 10 ml volume~* 0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~* 0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding.
Study: NCT05752799
Drug: Opioid based anesthesia
Normalized name: Opioid anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 2 mcg/kg fentanyl in 10 ml volume~* 0.2 mL/kg/h remifentanil infusion~* 0.1 mg/kg morphine. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding.
Study: NCT05105542
Drug: 11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: The radiotracer, \[11C\]EMO, will be administered at the beginning of each PET scan.
Study: NCT06640257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04866160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06120088
Drug: Bubpivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine is a long-acting local anesthetic commonly used to provide pain relief by blocking nerve signals in a specific area. It's often utilized for various medical procedures and surgeries, offering prolonged numbing effects.
Study: NCT06120088
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl is a powerful synthetic opioid pain reliever. It acts on the central nervous system to alleviate severe pain. Fentanyl is significantly potent and is used in medical settings for acute pain management, such as during surgeries or for chronic pain in cases where other opioids may not be as effective.
Study: NCT05835011
Drug: Decitabine/Cedazuridine
Normalized name: decitabine/cedazuridine 35 mg-100 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral FDC tablets administration
Study: NCT04807309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day
Study: NCT05924191
Drug: Placebo Corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 hour before the surgery a placebo tablet, with the same physical and organoleptic characteristics, composed of corn starch, without harmful effects on health and simulating Dexamethasone (Celsius Laboratory, Montevideo, Uruguay).).
Study: NCT05924191
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)
Study: NCT05846490
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive treatment intensification (if necessary)
Study: NCT06371495
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stude include three groupsof people GroupA: recieve rosuvastatin 40mg Group B :recive rosuvastatin 20mg Group C: recive placebo 2- Follow up will be done using NIHSS at the onset and modified Rankin scale at the onset and after 1 month and 3 months of the onset.~3- Carotid duplex will be done at the onset and after 1 month and 3 months of the onset.
Study: NCT06140758
Drug: 1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Study: NCT06177535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three capsules orally once daily within one hour of bedtime. Looks exactly like the study drug, but it contains no active ingredient.
Study: NCT05924425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized in the control group will receive the placebo every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
Study: NCT06666283
Drug: AP303 150μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP303 Tablet 150μg QD
Study: NCT06666283
Drug: AP303 300μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP303 Tablet 300μg QD
Study: NCT06666283
Drug: Placebo 150μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet 150μg QD
Study: NCT06666283
Drug: Placebo 300μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet 300μg QD
Study: NCT06148038
Drug: CBD Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD Oral 350mg twice daily for 28 days
Study: NCT06252493
Drug: Radiotracer Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Gallium-68 labeled collagen binding probe 8 (\[68Ga\]CBP8):~All subjects will undergo placement of an intravenous catheter (IV). The catheter will be flushed post-injection of \[68Ga\]CBP8 with 0.9% saline solution.~The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used as needed to enable the patient to comfortably maintain his/her position throughout the scan; Up to 15 mCi of \[68Ga\]CBP8 will be administered. The injected dose and the time of injection will be recorded;~Post scan:~The catheter will be removed. The subject will be asked to void again immediately after the scan and he/she will be counseled on the importance of continuing to drink fluids for several more hours in order to increase urine flow rate and minimize the radiation dose to the bladder wall.
Study: NCT06252493
Drug: Contrast Media, Magnetic Resonance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dotarem 20ml will be injected during acquisition of contrast enhanced T1weighted fat saturated sequences, in keeping with standard of care MR enterography.
Study: NCT06252493
Drug: Oral contrast media application
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be invited to drink as much as possible of an oral contrast solution consisting of a mixture of 1500-2000 ml of dilute barium or sorbitol (VoLumen or Breeza) and water. Breeza, and in the past VoLumen, is routine clinical practice at MGH. The solution comes already prepared in bottles, so there is no need to dilute or prepare. The investigators will just hand the bottle to the patient and will ask the patient to start drinking \~1 hour before the scan. By routine practice at MGH, the investigators give 3-4 bottles of Breeza, about 1500-2000ml.
Study: NCT06160895
Drug: TQ-A3334 placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.
Study: NCT05879523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous, single dose, multiple doses
Study: NCT05628038
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Study: NCT05628038
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)
Study: NCT04799054
Drug: TransCon TLR7/8 Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon TLR7/8 Agonist will be administered as an IT injection
Study: NCT06574594
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate discontinuation group : stop MTX for 2 weeks after each shingrix vaccination
Study: NCT06574594
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate continuation group : keep methotrexate
Study: NCT05929768
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05929768
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04694989
Drug: D013, D326, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05694884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT05694884
Drug: ASLAN004
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASLAN004
Study: NCT05905653
Drug: STN1012600 ophthalmic solution 0.002%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days
Study: NCT05277051
Drug: GSK4381562
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4381562 will be administered.
Study: NCT05277051
Drug: GSK5764227
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK5764227 will be administered.
Study: NCT04740827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant matching placebo tablets.
Study: NCT05223647
Drug: Chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
Study: NCT04614610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% 100mL over 10 minutes
Study: NCT06685354
Drug: hepatic arterial infusion of recombinant human type 5 adenovirus
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive hepatic arterial infusion of recombinant human type 5 adenovirus (H101). The H101 treatment regimen consists of 3 cycles or until a specific treatment discontinuation event occurs as outlined in the protocol. The H101 administration method is as follows: if the sum of the largest diameters of lesions is ≤10 cm, the total dose is 1.0×10\^12 vp (2 vials); if the sum of the largest diameters is \&gt;10 cm, the total dose is 1.5×10\^12 vp (3 vials). Treatment cycles are every 3 weeks.
Study: NCT06668727
Drug: HepB mAb19
Normalized name: HepB-CpG
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study has two parts:~Part A will involve administering a single ascending dose of HepB mAb19 or placebo using a randomized, double-blind method in Groups 1-3 at dose levels of 3, 10, and 30 mg/kg. Participants enrolled in Groups 1-3 will be randomized at a 3:1 ratio to receive HepB mAb19 or placebo. Part B will assess the maximum tolerated dose (MTD) in Group 4 in an openlabel fashion. Participants will receive HepB mAb19 at MTD.
Study: NCT05607680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously (SC) once a week.
Study: NCT05607680
Drug: IBI362
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI362 administered subcutaneously (SC) once a week.
Study: NCT06684197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be used instead of dexmedetomidine
Study: NCT04308278
Drug: 2LEBV® / 2LXFS®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study: NCT04308278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study: NCT05709028
Drug: Standard of care antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care antibiotics will be chosen by the treating clinician according to institutional prescribing practices, local antibiograms and medication availability.
Study: NCT06223971
Drug: [11C]CPPC Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.~Other Name: \[5-cyano-N-(4-(4-\[11C\]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide\]
Study: NCT06205628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT05550909
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines
Study: NCT05887271
Drug: Low calorie meal replacement plan
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal replacement diet containing \~850 kcal/day (40% protein, 50% carbohydrate, 10% fat) supplied by Counterweight® (www.counterweight.org).The meal replacement plan will comprise of 3-4 meal packs/day (to equate to 850 kcal) with sweet and savoury options, and an allowance of 100ml semi-skimmed milk or a non-dairy alternative.
Study: NCT05181735
Drug: Eprex
Normalized name: Eprex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoietin alfa will be adminstered as a subcutaneous injection at the selected dose according to part A : 30 000 UI/week or 60 000 UI/week, every week
Study: NCT05802407
Drug: Later-line therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Another chemotherapy regimen, targeted therapy, or immunotherapy
Study: NCT06010693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one placebo matched to daridorexant 50 mg tablet , orally, once daily for about 28 consecutive nights on each night approximately 30mintues before participants intends to try to sleep.
Study: NCT05231772
Drug: Saccharomyces Boulardii Probiotic Supplement
Normalized name: Saccharomyces boulardii Chewable Tablet [Rezyst Probiotic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yeast
Study: NCT05231772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05601323
Drug: Nal-IRI/FL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanoliposomal irinotecan, Fluorouracil, Levofolinate
Study: NCT05601323
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin
Study: NCT05601323
Drug: Gem/nab-PTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine, nab-Paclitaxel
Study: NCT06619314
Drug: MK-1084
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06619314
Drug: PPI
Normalized name: PPIase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT05194761
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using normal saline nebulization in neonates postextubation
Study: NCT05212662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator supplied in vials identical to the active intervention, TTI-0102
Study: NCT04356326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
Study: NCT06389760
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive mFOLFIRINOX as follows: Oxaliplatin 65 mg/m2 on Day 1 and 15 of a 28-day cycle; Irinotecan 130 mg/m2 on Day 1 and 15 of a 28-day cycle; Leucovorin(LV) 200 mg/m2 Day 1 and 15 of a 28-day cycle; 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day 1 and 15 of a 28-day cycle (6 cycles).
Study: NCT04603300
Drug: INT301
Approvals — FDA: no, EMA: no, PMDA: no
Description: INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste
Study: NCT04905602
Drug: SHR-1905/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose
Study: NCT05753865
Drug: SYHX2011
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion, 260 mg/m\^2
Study: NCT04603300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully functional toothpaste containing no immunotherapy agents